Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Schorb

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Haematologica|December 11, 2025
Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma - a retrospective multicentre clinical studyKudret Kama, Hannes Treiber, Alexandra Kutilina, et al.
British Journal of Haematology|May 27, 2020
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysisEliza M Lauer, Miguel Waterhouse, Moritz Braig, et al.
The Journal of Molecular Diagnostics : JMD|August 4, 2020
Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral BiopsyManuel Montesinos-Rongen, Anna Brunn, Armin Tuchscherer, et al.
Haematologica|January 10, 2013
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantationElisabeth Schorb, Benjamin Kasenda, Johannes Atta, et al.
Hematological Oncology|August 17, 2019
Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysisAndreas M Schmitt, Amanda K Herbrand, Christopher P Fox, et al.
British Journal of Haematology|January 31, 2020
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practiceElisabeth Schorb, Christopher P Fox, Benjamin Kasenda, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
Neurology|May 21, 2013
Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphomaNancy D Doolittle, Agnieszka Korfel, Meredith A Lubow, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 9, 2025
Comparison of survival and progression after focal- or whole brain radiotherapy in patients with primary CNS lymphoma - Results from a large multicenter analysis of the German Society of Radiation Oncology's Neuro-Radio-Oncology Working Group (DEGRO AG-NRO)Sina Heider, Luisa Allwohn, Alexander Rühle, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Haematologica|December 11, 2025
Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma - a retrospective multicentre clinical studyKudret Kama, Hannes Treiber, Alexandra Kutilina, et al.
British Journal of Haematology|May 27, 2020
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysisEliza M Lauer, Miguel Waterhouse, Moritz Braig, et al.
The Journal of Molecular Diagnostics : JMD|August 4, 2020
Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral BiopsyManuel Montesinos-Rongen, Anna Brunn, Armin Tuchscherer, et al.
Haematologica|January 10, 2013
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantationElisabeth Schorb, Benjamin Kasenda, Johannes Atta, et al.
Hematological Oncology|August 17, 2019
Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysisAndreas M Schmitt, Amanda K Herbrand, Christopher P Fox, et al.
British Journal of Haematology|January 31, 2020
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practiceElisabeth Schorb, Christopher P Fox, Benjamin Kasenda, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
Neurology|May 21, 2013
Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphomaNancy D Doolittle, Agnieszka Korfel, Meredith A Lubow, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 9, 2025
Comparison of survival and progression after focal- or whole brain radiotherapy in patients with primary CNS lymphoma - Results from a large multicenter analysis of the German Society of Radiation Oncology's Neuro-Radio-Oncology Working Group (DEGRO AG-NRO)Sina Heider, Luisa Allwohn, Alexander Rühle, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Pageof 5